Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
In this head-to-head trial, mazdutide outperformed dulaglutide on both glycemic control and weight reduction in adults with type 2 diabetes over 28 weeks, with a safety profile similar to other GLP-based therapies.
